Literature DB >> 32797405

Prognostic role of uterine artery Doppler in early- and late-onset preeclampsia with severe features.

Keerthi Chilumula1, Pradip Kumar Saha2, Tanuja Muthyala1, Subhas Chandra Saha1, Venkataseshan Sundaram3, Vanita Suri1.   

Abstract

OBJECTIVE: To correlate uterine artery Doppler findings with maternal and neonatal outcomes in early- and late-onset preeclampsia with severe features.
METHODOLOGY: Doppler scan was done in both uterine arteries. Maternal and neonatal outcomes in women with abnormal and normal Doppler results were compared.
RESULTS: Abnormal Doppler results were present in 45 women (75%). Thirty-four (56.7%) women had abnormal RI, 19 (31.6%) had abnormal PI, and 36 (60%) had diastolic notch. Of the women who participated in the study, 21.6% developed maternal complications, and the majority belonged to the early-onset severe preeclampsia group. Diastolic notch was twofold more frequent in the early group. RI was abnormal in 63% of the early-onset and 50% of the late-onset group.
CONCLUSION: Pregnancies with early-onset preeclampsia who had abnormal uterine artery Doppler findings were at high risk for both maternal and neonatal complications, whereas those who had late-onset preeclampsia with abnormal Doppler findings only had an increased risk of perinatal complications.
© 2020. Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB).

Entities:  

Keywords:  Maternal outcome; Neonatal outcome; Preeclampsia; Uterine artery Doppler

Mesh:

Year:  2020        PMID: 32797405      PMCID: PMC8363681          DOI: 10.1007/s40477-020-00524-0

Source DB:  PubMed          Journal:  J Ultrasound        ISSN: 1876-7931


  21 in total

Review 1.  Care of the critically ill parturient: oliguria and renal failure.

Authors:  G D Mantel
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2001-08       Impact factor: 5.237

2.  Can uterine artery Doppler velocimetry predict adverse pregnancy outcome in women with antiphospholipid syndrome?

Authors:  T Farrell; T Dawson
Journal:  Acta Obstet Gynecol Scand       Date:  2001-07       Impact factor: 3.636

Review 3.  Subclassification of preeclampsia.

Authors:  Peter von Dadelszen; Laura A Magee; James M Roberts
Journal:  Hypertens Pregnancy       Date:  2003       Impact factor: 2.108

4.  Increased uterine artery vascular impedance is related to adverse outcome of pregnancy but is present in only one-third of late third-trimester pre-eclamptic women.

Authors:  H Li; H Gudnason; P Olofsson; M Dubiel; S Gudmundsson
Journal:  Ultrasound Obstet Gynecol       Date:  2005-05       Impact factor: 7.299

5.  The prognostic role of uterine artery Doppler investigation in patients with severe early-onset preeclampsia.

Authors:  Eva Meler; Francesc Figueras; Mar Bennasar; Olga Gomez; Fatima Crispi; Eduard Gratacos
Journal:  Am J Obstet Gynecol       Date:  2010-03-29       Impact factor: 8.661

6.  Doppler criteria for intrauterine growth retardation: predictive values.

Authors:  C B Benson; P M Doubilet
Journal:  J Ultrasound Med       Date:  1988-12       Impact factor: 2.153

7.  Third-trimester uterine artery Doppler measurement and maternal postpartum outcome among patients with severe pre-eclampsia.

Authors:  Ahmed M Maged; Noura ElNassery; Mona Fouad; Aly Abdelhafiz; Walaa Al Mostafa
Journal:  Int J Gynaecol Obstet       Date:  2015-06-18       Impact factor: 3.561

8.  Uterine artery velocimetry in patients with gestational hypertension.

Authors:  T Frusca; M Soregaroli; C Platto; L Enterri; A Lojacono; A Valcamonico
Journal:  Obstet Gynecol       Date:  2003-07       Impact factor: 7.661

Review 9.  Diagnosis and management of gestational hypertension and preeclampsia.

Authors:  Baha M Sibai
Journal:  Obstet Gynecol       Date:  2003-07       Impact factor: 7.661

10.  Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.

Authors:  Douglas Altman; Guillermo Carroli; Lelia Duley; Barbara Farrell; Jack Moodley; James Neilson; David Smith
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.